Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL7279040 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1FKBP5SLC1A3SLC1A2 | |
| Valine SCHEMBL645699 | 1.00 | SLC7A5 (0.54) | SLC7A5ALDH1A1FKBP5SLC1A3SLC1A2 | |
| Threonine SCHEMBL28637557 | 0.89 | ALDH1A1 (0.46) | SLC7A5ALDH1A1FKBP5SLC1A3SLC1A2 | |
| Threonine SCHEMBL28155188 | 0.89 | ALDH1A1 (0.46) | SLC7A5ALDH1A1FKBP5SLC1A3SLC1A2 | |
| Alanine SCHEMBL8532378 | 0.87 | ALDH1A1 (0.52) | SLC7A5ALDH1A1FKBP5CYP3A4 | |
| Alanine SCHEMBL8532370 | 0.87 | ALDH1A1 (0.52) | SLC7A5ALDH1A1FKBP5CYP3A4 | |
| Isoleucine SCHEMBL28155191 | 0.85 | ALDH1A1 (0.42) | SLC7A5ALDH1A1FKBP5 | |
| Imidazole SCHEMBL2158081 | 0.83 | ALDH1A1 (0.56) | ALDH1A1FKBP5 | |
| Lactic Acid SCHEMBL1331765 | 0.81 | ALDH1A1 (0.54) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL16859470 | 0.79 | ALDH1A1 (0.52) | ALDH1A1FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106966988-A | A kind of method of use microwave radiation synthesizing amino acid imidazole salts in aqueous | 上海应用技术大学 | 2017-07-21 | — | — | CN | disclosed |
| CN-106604734-A | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | 艾丽奥斯生物制药有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106573011-A | Substituted nucleosides, nucleotides and analogs thereof | 艾丽奥斯生物制药有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7629477-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | SLC7A5 3236/4885ALDH1A1 2088/4885FKBP5 666/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | SLC7A5 3608/4885ALDH1A1 2715/4885FKBP5 1151/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | SLC7A5 3608/4885ALDH1A1 2715/4885FKBP5 1151/4885 |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | SLC7A5 3608/4885ALDH1A1 2715/4885FKBP5 1151/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | SLC7A5 3608/4885ALDH1A1 2715/4885FKBP5 1151/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | SLC7A5 3608/4885ALDH1A1 2715/4885FKBP5 1151/4885 |
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | SLC7A5 3608/4885ALDH1A1 2715/4885FKBP5 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.